Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 5/20 | 0.57 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.56 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.45 |
| ▸ | SCN4A | P35499 | 2/20 | 0.44 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | TDO2 | P48775 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1977034 | 1.00 | SLC6A4 (0.57) | SLC6A4ADRB2SLC6A3SLC6A2SCN4A | |
| SCHEMBL12262253 | 1.00 | SLC6A4 (0.57) | SLC6A4ADRB2SLC6A3SLC6A2SCN4A | |
| Hydrochloric Acid SCHEMBL16292773 | 0.98 | SLC6A4 (0.55) | SLC6A4ADRB2SLC6A3SLC6A2SCN4A | |
| SCHEMBL23092069 | 0.87 | SLC6A4 (0.70) | SLC6A4ADRB2SLC6A3SLC6A2SCN4A | |
| SCHEMBL8284225 | 0.83 | SLC6A4 (0.59) | SLC6A4ADRB2SLC6A3SLC6A2IDO1 | |
| SCHEMBL8285910 | 0.83 | SLC6A4 (0.59) | SLC6A4ADRB2SLC6A3SLC6A2IDO1 | |
| SCHEMBL9198692 | 0.82 | ADRB2 (0.52) | SLC6A4ADRB2SLC6A3SLC6A2SCN4A | |
| Hydrochloric Acid SCHEMBL4938618 | 0.81 | SLC6A4 (0.57) | SLC6A4ADRB2IDO1MAPK1HIF1A | |
| Hydrochloric Acid SCHEMBL4935308 | 0.81 | SLC6A4 (0.57) | SLC6A4ADRB2IDO1MAPK1HIF1A | |
| Ammonia Solution, Strong SCHEMBL386864 | 0.80 | ADRB2 (0.50) | SLC6A4ADRB2SLC6A3SLC6A2SCN4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3994125-B1 | MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF | REGENERON PHARMA (US) | 2025-12-24 | — | — | EP | disclosed |
| US-12252495-B2 | Protein kinase B inhibitors | ASTRAZENECA AB (SE) | 2025-03-18 | — | — | US | disclosed |
| US-20240299402-A1 | MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2024-09-12 | — | — | US | disclosed |
| US-11957687-B2 | Modulators of HSD17B13 and methods of use thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2024-04-16 | — | — | US | disclosed |
| US-20240109902-A1 | PROTEIN KINASE B INHIBITORS | ASTRAZENECA AB (SE) | 2024-04-04 | — | — | US | disclosed |
| US-11760760-B2 | Protein kinase B inhibitors | ASTRAZENECA AB (SE) | 2023-09-19 | — | — | US | disclosed |
| US-20230094341-A1 | MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2023-03-30 | — | — | US | disclosed |
| US-20220220116-A1 | PROTEIN KINASE B INHIBITORS | ASTRAZENECA AB (SE) | 2022-07-14 | — | — | US | disclosed |
| EP-3994125-A1 | MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF | Regeneron Pharmaceuticals, Inc. (US) | 2022-05-11 | — | — | EP | disclosed |
| US-11236095-B2 | Protein kinase B inhibitors | ASTRAZENECA AB (SE) | 2022-02-01 | — | — | US | disclosed |
| WO-2005090348-A1 | PYRAZOLO ’3,4-B! PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE TYPE 4 (PDE4) INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-09-29 | — | — | WO | disclosed |
| WO-2005058892-A1 | PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-06-30 | — | — | WO | disclosed |
| EP-1373192-A1 | N-PHENPROPYLCYCLOPENTYL-SUBSTITUTED GLUTARAMIDE DERIVATIVES AS NEP INHIBITORS FOR FSAD | Pfizer Limited (GB) | 2004-01-02 | — | — | EP | disclosed |
| WO-2002079143-A1 | N-PHENPROPYLCYCLOPENTYL-SUBSTITUTED GLUTARAMIDE DERIVATIVES AS NEP INHIBITORS FOR FSAD | PFIZER LIMITED (GB) | 2002-10-10 | — | — | WO | disclosed |
| US-5017723-A | Psychotropic Agents | JOUVEINAL S.A. (FR) | 1991-05-21 | — | — | US | disclosed |
| EP-0210044-B1 | HYDROXY AND ALKOXY PYRIMIDINES | PFIZER INC. (US) | 1990-08-29 | — | — | EP | disclosed |
| US-4711888-A | Hydroxy and alkoxy pyrimidines | PFIZER INC. (US) | 1987-12-08 | — | — | US | disclosed |
| EP-0210044-A2 | Hydroxy and alkoxy pyrimidines | PFIZER INC. (US) | 1987-01-28 | — | — | EP | disclosed |
| US-4622324-A | CARDIOVASCULAR DISORDERS, HYPOTENSIVES | DR. WILLMAR SCHWABE GMBH & CO. (DE) | 1986-11-11 | — | — | US | disclosed |
| US-4479951-A | CORONARY DIESASE | DR. WILLMAR SCHWABE GMBH & CO. (DE) | 1984-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12252495-B2 | Protein kinase B inhibitors | PRKAR2B, PRKCB, AKT1 | SLC6A4 4654/4885ADRB2 1451/4885SLC6A3 4750/4885 |
| US-20220220116-A1 | PROTEIN KINASE B INHIBITORS | PRKAR2B, PRKCB, AKT1 | SLC6A4 4654/4885ADRB2 1451/4885SLC6A3 4750/4885 |
| US-20240299402-A1 | MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF | HSD17B3, HSD17B11, HSD17B1 | SLC6A4 2816/4885ADRB2 1854/4885SLC6A3 2221/4885 |
| US-20240109902-A1 | PROTEIN KINASE B INHIBITORS | PRKAR2B, PRKCB, AKT1 | SLC6A4 4654/4885ADRB2 1451/4885SLC6A3 4750/4885 |
| US-20230094341-A1 | MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF | HSD17B3, HSD17B11, HSD17B1 | SLC6A4 2816/4885ADRB2 1854/4885SLC6A3 2221/4885 |
| US-11236095-B2 | Protein kinase B inhibitors | PRKAR2B, PRKCB, AKT1 | SLC6A4 4654/4885ADRB2 1451/4885SLC6A3 4750/4885 |
| US-11760760-B2 | Protein kinase B inhibitors | PRKAR2B, PRKCB, AKT1 | SLC6A4 4654/4885ADRB2 1451/4885SLC6A3 4750/4885 |
| US-11957687-B2 | Modulators of HSD17B13 and methods of use thereof | HSD17B3, HSD17B11, HSD17B1 | SLC6A4 2816/4885ADRB2 1854/4885SLC6A3 2221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.